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Nef, a multifunctional accessory protein of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), is important
for disease progression. Nef downmodulates CD4 and MHC class I expression, alters host-cell signal transduction pathways, and enhances
viral replication. We have identified a novel interaction between Nef and cAMP-dependent kinase (PKA). N-terminal serine residues Ser6,9 of
HIVNL4-3 Nef and Ser
10 of SIVmac239 Nef were phosphorylated by PKA in a cell-free system; intracellularly, only Ser9 of HIVNL4-3 Nef was
phosphorylated by PKA. Mutation of Ser9 to alanine in the context of full-length HIVNL4-3 lowered HIV replication in resting peripheral
blood mononuclear cells (PBMC) compared to parental virus. As this mutation played a major role in abrogating the Nef effect on HIV
replication in unstimulated primary cells, we postulate that Nef phosphorylation by PKA is an important step in the viral life cycle in resting
cells.
D 2004 Elsevier Inc. All rights reserved.
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Expression of full-length Nef, a 27- to 35-kDa accessory
protein of human immunodeficiency virus (HIV) and simian
immunodeficiency virus (SIV), is associated with high viral
loads and disease progression. Nef is expressed in the
earliest stages of the viral life cycle, even before viral DNA
integrates into the host genome (Wu and Marsh, 2001); Nef
is modified post-translationally by phosphorylation and
myristoylation. In vitro, Nef down-regulates expression of
CD4 and major histocompatibility complex (MHC) class I
molecules from the cell surface (Garcia and Miller, 1991;
Schwartz et al., 1996) and enhances viral replication in
unstimulated, resting peripheral blood mononuclear cells
(PBMC) and primary CD4+ T cells (Miller et al., 1994;
Spina et al., 1994). Although the mechanism behind Nef’s0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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associates with cellular proteins. Nef’s interactions with
members of the tyrosine and serine protein kinase family
alter cellular signal transduction pathways, enhancing viral
replication (Fackler and Baur, 2002; Geyer et al., 2001;
Renkema and Saksela, 2000).
Previous work has shown that Nef phosphorylation by
serine protein kinases contributes to the regulation of Nef
activity. Phosphorylation of N-terminal Nef residues by
serine kinases impacts virion infectivity (Baur et al., 1997);
Nef phosphorylation by protein kinase C (PKC), a serine
family protein kinase, enhances CD4 down-regulation (Luo
et al., 1997). PKA is a key serine protein kinase in the cyclic
adenosine monophosphate (cAMP) signaling pathway that
regulates T cells (Shabb, 2001). Increasing PKA activity can
enhance HIV transcription (Kagnoff and Roebuck, 1999;
Rabbi et al., 1998) and virus replication (Kagnoff and
Roebuck, 1999; Nokta and Pollard, 1992). Moreover, HIV-
positive individuals have shown significantly increased
cAMP/PKA activity in T cells as well as impaired T-cell
function; furthermore, reducing intracellular PKA activity05) 367–374
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(Aandahl et al., 1998; Hofmann et al., 1993). Recently,
another link between PKA and HIV was shown; Cartier et
al. (2003) demonstrated that PKA is incorporated into HIV
virions and plays an important role in HIV infectivity and
replication in a single-cycle assay.
Thus far, indirect evidence has shown that PKA has been
involved in HIV transcription and replication. Earlier studies
concluding that PKA had no effect on Nef phosphorylation
were largely based upon the use of phorbol myristate acetate
(PMA), a PKC stimulator (Luo et al., 1997). We discovered
that the N-terminus of Nef could potentially serve as a PKA
substrate according to the consensus sites in physiological
substrates of PKA (Shabb, 2001), and we used this
information to study Nef’s interactions with PKA. Here
we report that PKA phosphorylates Nef proteins and that
mutation of the PKA phosphorylation site in Nef impacts
HIV replication in quiescent primary cells.Results
PKA phosphorylation of Nef in vitro
We used a cell-free in vitro assay to determine whether
PKA can phosphorylate Nef. Wild-type nef genes were
amplified from HIVNL4-3, HIV clade C (Indie-C1; Mochi-Fig. 1. Phosphorylation of Nef by PKA in vitro. (A) Alignment of N-terminal Nef
S8A as well as SIV S10A). Amino acid changes from the wild-type sequence are
impact phosphorylation, but a mutation outside these sites has no effect. After a
different Nef–GST fusion proteins. The PKA assay was performed three times ind
present in the same amounts in the PKA phosphorylation reaction as shown by S
mutations in the PKA phosphorylation sites showed reduced levels of phosphory
*Indicates this result is statistically significant (P b 0.001 with Bonferroni’s corrzuki et al., 1999), and SIVmac239 nef open by PCR and
cloned into the GST fusion protein vector pGEX-6p-1; all
clones were confirmed by sequencing. All wild-type (Wt)
GST–Nef fusion proteins tested were phosphorylated in an in
vitro PKA protein kinase assay (Figs. 1B and D, protein from
HIV clade C not shown), while purified GST protein (Figs.
1B and D, lanes 5 and 8) was not phosphorylated.
Subsequent mass spectral analysis showed that Ser10 of
SIVmac239 Nef and Ser6 and Ser9 of HIVNL4-3 Nef had been
phosphorylated (not shown). While S6 is part of the
myristoylation signal of Nef (Resh, 1999), S9 is not.
To verify that these Ser residues were substrates for PKA,
we constructed Nef mutants by changing Ser6 and Ser9 to
Ala in HIVNL4-3 to yield Nef S6,9A, Ser
9 to Ala in HIVNL4-3
to produce Nef S9A, and Ser10 to Ala in SIVmac239 Nef
open to generate Nef S10A (Fig. 1A). PKA assays with
these mutant proteins showed that HIV S6,9A Nef and SIV
S10A Nef were no longer phosphorylated by PKA, whereas
the single-mutant HIV S9A Nef was phosphorylated to a
lesser degree (Figs. 1B and D). Protein input was equal in all
assays (Fig. 1C).
To explore the specificity of Nef’s interaction with PKA,
we mutated Ser8 to Ala in HIVNL4-3 Nef (S8A, Fig. 1A). This
residue was not phosphorylated by the PKA catalytic subunit
according to mass spectral analysis but is located adjacent to
the Ser9 phosphorylation site. The S8A mutation did not
affect Nef phosphorylation by PKA (Figs. 1B and D), thussequences of both wild-type and mutant constructs (HIV S6,9A, S9A, and
indicated by underline. (B) Mutations at putative Nef phosphorylation sites
n in vitro incubation with PKA, we quantified 32P incorporation into the
ependently. (C) Mutated and wild-type (Wt) Nef–GST fusion proteins were
DS-PAGE. (D) Autoradiography of the same gel as panel C. Proteins with
lation compared to wild-type Nef. M: protein molecular weight standard
ection)..
Fig. 3. Nef is phosphorylated by PKA in cells. (A) PKA co-immunopre-
cipitates with Nef. 293T cells were transfected with an expression vector
encoding wild-type HIVNL4-3 nef or an empty vector. At 24 h post-
transfection, cells were stimulated with the PKA activator forskolin (30 min)
and subjected to immunoprecipitation with anti-HIV Nef serum. Immuno-
precipitated proteins were then analyzed by Western blot, using monoclonal
antibodies against the catalytic subunit of PKA (lanes 1–3) and against HIV
Nef (lanes 4–6). PKA (40 kDa catalytic subunit, lane 1) served as a positive
control for anti-PKA. Lanes 2 and 4, lysates from cells transfected with
wild-type HIVNL4-3 nef vector (Tfx nef-vector) showed that PKA had been
co-immunoprecipitated with anti-Nef (correctly sized band is marked by an
asterisk). Lysates of cells transfected with empty vector (Tfx vector) (lanes
3 and 5) showed neither PKA nor Nef. Lane 6, positive control, HIVNL4-3
Nef. Monoclonal anti-PKA antibody did not bind to Nef alone, nor did
monoclonal anti-HIV Nef antibody bind to PKA alone (data not shown).
(B–D) 293T cells were transfected as described in (A); at 24 h post-
transfection, the cells were pulsed with [32P] orthophosphate and stimulated
with forskolin, with or without the PKA inhibitor H-89. Nef was
immunoprecipitated from the cleared lysate with anti-HIV Nef serum. (B)
According to Western blot, Nef was expressed at the same level in cells in
the presence or absence of H-89. (C) H-89 decreased Nef phosphorylation
in cells. Autoradiography of the Western blot membrane showed that the
P.L. Li et al. / Virology 331 (2005) 367–374 369indicating that Ser6 and Ser9 of HIVNL4-3 Nef and Ser
10 of
SIVmac239 Nef serve as specific substrates for PKA
phosphorylation.
To confirm that HIV Nef is a PKA substrate with two
potential phosphorylation sites for PKA, the stoichiometry
of HIVNL4-3 Nef phosphorylation by the PKA catalytic
subunit was studied in a cell-free system. PKA treatment
resulted in serine phosphorylation with a stoichiometry of
1.8 F 0.19 mol of phosphate/mol of GST-wild-type
HIVNL4-3 Nef (Wt), consistent with two phosphorylation
sites. When the single mutant (GST-Nef S9A) was treated
with PKA, the stoichiometry was approximately 20-fold
lower at 0.095 F 0.012 mol of phosphate/mol, whereas for
the double mutant GST-Nef S6,9A and for GST alone, no
phosphorylation was detected (Fig. 2). This kinetic result
confirmed that wild-type HIVNL4-3 Nef, but not its S6,9A
double mutant, was a good substrate for PKA.
Intracellular PKA phosphorylation of Nef
Although we showed that PKA could phosphorylate Nef
at specific serine residues in a cell-free system in vitro, we
also sought to examine PKA’s intracellular interactions with
Nef. First, a co-immunoprecipitation assay was performed
to determine whether Nef associates with PKA in the
cytoplasm. 293T cells were transfected with either a
mammalian expression vector encoding HIVNL4-3 nef or
an empty vector and stimulated 24 h post-transfection with
the PKA activator forskolin. After lysis, immunoprecipita-
tion was performed with anti-HIV Nef serum. Western blot
analysis with either monoclonal anti-catalytic subunit of
sample without H-89 (lane 2) had higher levels of 32P phosphorylation
compared to control (lane 1) or the sample containing H-89 (lane 3). (D)
H-89 reduced the amount of [32P] incorporated into Nef in cells. Nef bands
were excised from the membrane, and [32P] was quantified. The sample
without H-89 contained higher levels of [32P] than the sample with H-89
( P b 0.001).This assay was performed three times independently. **Indi-
cates this result is significant with P b 0.001 after Bonferroni’s correction.
Fig. 2. PKA phosphorylation of Nef. Different Nef–GST fusion proteins or
GST protein alone were incubated with [g-32P]ATP and PKA (catalytic
subunit) as described in the text. Kinetic data were analyzed by nonlinear
regression to fit the data to the Michaelis–Menten equation: V = Vmax[X] /
(Km + [X]) by using PRISM as described in Materials and methods. Each
point represents the mean F SEM of four experiments. Wild-type (Wt)
Nef–GST (closed squares); single-mutant Nef (S9A)–GST (open squares);
double-mutant Nef (S6,9A)–GST (open triangles), and GST alone (open
circles).PKA (Fig. 3A, lanes 1–3) or monoclonal anti-Nef (Fig. 3A,
lanes 4–6) antibodies showed that the catalytic subunit of
PKA had been co-immunoprecipitated with anti-HIV Nef
serum (Fig. 3A, lane 2; correctly sized band marked by
asterisk). The band of 40 kDa identified in lane 2
corresponds in molecular mass to the catalytic subunit of
PKA and indicates that the latter bound Nef intracellularly.
An intracellular phosphorylation assay was then used to
investigate whether this association could result in Nef
phosphorylation by PKA. After the same transfection
procedure, 293T cells were labeled with [32P] orthophos-
phate and stimulated for 30 min with the PKA activator
forskolin, with or without H-89, a selective inhibitor of
PKA. Lysates were immunoprecipitated with anti-HIV Nef
serum and analyzed by Western blot (Fig. 3B) followed by
autoradiography (Fig. 3C). Nef bands were cut out from the
filter to quantitate [32P] incorporation into Nef (Fig. 3D).
Nef was expressed at the same level regardless of the
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amount of [32P] incorporated into Nef in the presence of H-
89 (Figs. 3C and D, lane 3) was significantly lower than in
the sample without H-89 (Fig. 3C and D, lane 2) (P b
0.001). The precipitated proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and the
[32P]-labeled band corresponding to Nef was excised and
examined by mass spectral analysis, which confirmed that
only Ser9 of HIVNL4-3 Nef had been phosphorylated (not
shown). This finding was in contrast to the in vitro PKA
assay with recombinant Nef, which showed that both Ser6
and Ser9 were phosphorylated; however, because Ser6 is part
of the myristoylation signal, intracellular phosphorylation of
this site was not expected.
PKA phosphorylation of Nef impacts HIV replication
As one of Nef’s important functions is enhancement of
viral infectivity (Aiken and Trono, 1995; Schwartz et al.,
1995), we next investigated whether Nef phosphorylation by
PKA could affect viral replication. Using site-directed
mutagenesis on the full-length HIVNL4-3 provirus, we
constructed two isogenic HIV variants containing either
single or double mutations at the PKA phosphorylation sites
in nef. As a nef-negative control, we used a nef-deleted HIV
clone, HIVDnef (HIVNL4-3nef/SD; Spina et al., 1994).
Sequencing confirmed that single-mutant HIV S9A (with
Ser9 changed to Ala in nef) and double-mutant HIV S6,9A
(with Ser6 and Ser9 changed to Ala in nef) had only the
desired mutations in nef; no other viral genes were changed.
Viral stocks were generated by transfecting wild-type or
mutant proviral DNA into 293T cells, harvesting super-
natants, and standardizing by p24. Stimulated human PBMC
were infected with equivalent doses of either wild-typeFig. 4. Mutations at a putative PKA phosphorylation site in HIV nef reduced viral r
were infected with the same p24 doses of wild-type HIVNL4-3 (HIV, open squares),
HIVNL4-3nefS6,9A (HIV S6,9A, open diamonds), or the nef-deleted HIVNL4-3nef/
day 4 post-infection (p.i.) followed by culture in complete medium. Viral replicatio
p24 production from three independent infections with PBMC from three differen
wild-type HIV (open bar), and single-mutant HIV S9A (solid bar), double-mutanHIVNL4-3 (HIV), single-mutant HIV S9A, double-mutant
HIV S6,9A, or nef-deleted HIV (HIVDnef). HIVNL4-3
replication in stimulated PBMC was not affected by the nef
mutations (data not shown).
Other investigators have reported that enhancement of
viral replication by Nef can only be observed if resting
PBMC are exposed to virus and stimulation is postponed
for a few days thereafter (Spina et al., 1994; Wu and
Marsh, 2001). We therefore infected resting human PBMC
with the same p24 doses of either the wild-type or nef
mutant viruses and stimulated the cells 4 days later. HIV
S6,9A, HIV S9A, and HIVDnef replicated to significantly
lower levels compared to wild-type HIV (P b 0.03, P b
0.01, and P b 0.01, respectively) (Fig. 4). There was no
statistically significant difference between the replication
levels of the single mutant (S9A) and the double mutant
(S6,9A) (P = 0.08; not significant after Bonferroni’s
correction). However, there was a significant difference
between the replication levels of the double mutant (S6,9A)
and HIVDnef (P b 0.01). Overall, these data indicate that
the presence of serine at position 9 is critical for replication
in quiescent primary cells, and that regions beyond
S9, which were missing in HIVDnef, have additional
influence.
Finally, to ensure that the decreased viral output was due to
the removal of PKA phosphorylation sites in Nef, we directly
examined the impact of these Nef mutations on virus
replication using nef-deleted HIV and recombinant Nef
proteins provided in trans. It has been shown that HIV
generated from nef-deleted proviral DNA replicates to lower
levels in unstimulated, quiescent primary cells compared to
HIV expressed from wild-type provirus (Miller et al., 1994;
Spina et al., 1994); however, the replicative capacity can be
restored by co-expressing Nef in trans in the HIV-producingeplication in infected resting PBMC compared to wild-type HIV. (A) PBMC
single-mutant HIVNL4-3nefS9A (HIV S9A, solid diamonds), double-mutan
SD (HIVDnef, open circles). The virus-exposed PBMC were stimulated on
n was measured by p24 release into the supernatants. Results show average
t donors. (B) On day 10 p.i., a significant decrease in viral output between
t HIV S6,9A (hatched bar), or HIVDnef (striped bar) was noted.t
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assembly, but after the first cycle of replication, no further Nef
production can occur (Aiken and Trono, 1995; Miller et al.,
1995; Schwartz et al., 1995; Wu and Marsh, 2001). We co-
expressed the nef-deleted HIV clone HIVDnef (HIVNL4-3nef/
SD) in 293T cells with either wild-type or mutant Nefs in
trans to generate stocks of nef-deleted-HIV + Nef in trans.
Supernatants from cells co-transfected with nef-deleted HIV
and vectors expressing either wild-type Nef (HIVDnef +
Nef), single-mutant Nef (HIVDnef + Nef S9A) or double-
mutant Nef (HIVDnef + Nef S6,9A) were harvested, and p24
levels were measured. As control, we used supernatant
harvested from cells co-transfected with nef-deleted HIV
proviral DNA and the empty vector (HIVDnef + vector). Nef
expression was then assessed byWestern blot, which showed
equal levels of protein expression for all Nef variants in 293T
cells (Fig. 5A).
Next, resting human PBMC were infected with equiv-
alent p24 doses of HIVDnef + Nef, HIVDnef + Nef S9A,
HIVDnef + Nef S6,9A, or HIVDnef + empty vector, in a
single-cycle infection assay with regards to Nef. Nef-deleted
viruses co-expressed in trans with either single-mutant Nef
(HIVDnef + Nef S9A) or double-mutant Nef (HIVDnef +
Nef S6,9A) replicated to significantly lower levels com-
pared to virus co-expressed in trans with wild-type Nef
(HIVDnef + Nef) (P b 0.001 after Bonferroni correction)
(Fig. 5B); the same results were obtained in PBMC from
three different donors. As HIVDnef + Nef S9A displayed
the same low-level replication as nef-deleted HIV itself, we
conclude that the single point mutation of Ser9 to Ala9 wasFig. 5. Mutating the Nef PKA phosphorylation sites reduces HIV replication in a s
various Nef proteins in trans. (A) Western blot analysis from 293T cells were co-
separate expression vectors encoding either wild-type nef (Nef), single-mutant nef (
expressed at the same level by constructs encoding either wild-type or mutant nef g
co-transfection of 293T cells with nef-deleted HIV proviral DNA and expression ve
HIVDnef + Nef S9A (closed diamonds) and HIVDnef + Nef S6,9A (open diamon
and similar replication kinetics as HIVDnef + vector (open circles). Results show
obtained from three different donors. *Indicates this result is statistically significasufficient to abrogate the Nef-mediated enhancement of
viral replication in unstimulated primary cells.
To further examine whether the decreased viral output by
the Nef mutants was due to changes in viral infectivity, a
single-cycle infection assay was performed. We employed
TZM-bl cells, which are highly sensitive to infection with
diverse isolates of HIV (Wei et al., 2002). After 6 h of
exposure to viruses, the viral entry fusion inhibitor T20 was
added to the cells. Thus, this assay provided true single-
cycle conditions for both overall viral replication as well as
Nef proteins, which were provided in trans by cotransfection
as described above. We observed no significant differences
in the assays among HIVDnef + Nef, HIVDnef + Nef S9A,
HIVDnef + Nef S6,9A, or HIVDnef+ empty vector (data not
shown), indicating that the decreased viral output seen
previously in quiescent PBMC was due to the Nef mutants’
impact on viral replication in unstimulated primary cells
rather than virion infectivity.Discussion
To summarize, we have uncovered a novel interaction
between Nef and the host protein kinase PKA; we have
mapped the specific Nef residues phosphorylated by the
catalytic subunit of this enzyme in vitro and intracellularly
using mass spectroscopy and site-directed mutagenesis. We
confirmed that Nef serves as a specific PKA phosphoryla-
tion substrate in vitro by the stoichiometry of Nef
phosphorylation as well as by the response of the latter toingle-cycle infection assay of nef-deleted HIV assembled in cells expressing
transfected with nef-deleted HIVNL4-3nef/DS proviral DNA (HIVDnef) and
Nef S9A), double-mutant nef (Nef S6,9A) or empty vector (vector). Nef was
enes. (B) Infection of human PBMC with different virus stocks generated by
ctors described in A to yield virions co-packaged with different Nef proteins.
ds) had reduced viral replication compared to HIVDnef + Nef (open squares)
the average p24 production from three independent infections in PBMC
nt with P b 0.001 after Bonferroni’s correction.
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residue in full-length HIVNL4-3 proviral DNA, Nef-mediated
enhancement of viral replication in resting primary cells was
reduced. The specificity of this finding was confirmed in a
single-cycle assay with regards to Nef that involved
identical viral RNA backbones co-packaged with either
wild-type or mutated Nef proteins expressed in trans in
virus-producing cells. Thus, we have identified a specific
link between PKA-mediated Nef phosphorylation and HIV
replication in resting primary cells. As the Ser9 Nef point
mutation affected viral replication so drastically, we
postulate that Nef phosphorylation by PKA is an important
step in the viral life cycle in such cells.
The S9 PKA phosphorylation site was conserved in
approximately 76.5% of HIV Nef alleles we examined
through Gene Bank (http://www.ncbi.nlm.nih.gov/entrez).
We viewed at least 2,530 different Nef sequences from
isolates of groups M, N and O, including group M clades A,
B, C, D, F; we also examined sequences derived from recom-
binant strains of HIV, such as A/D or A/G. Additionally, a
study that examined sequence conservation among 186 HIV-
1 Nefs showed an 80% conservation rate of the S9 residue
(Geyer and Peterlin, 2001). Taken together, these independ-
ent observations suggest that the S9 PKA phosphorylation
site may be important for HIV Nef function. In SIVmac239
Nef, the PKA phosphorylation site was found at position S10.
In this context, it is interesting to consider the cellular
compartment(s) in which the PKA–Nef interaction could
take place. Both PKA (Skalhegg et al., 1994) and Nef
(Wang et al., 2000; Zheng et al., 2001), thanks to its myristic
acid side chain (Resh, 1999), are embedded in lipid rafts,
specialized microdomains on the plasma membrane that are
highly enriched in cholesterol and sphingolipids, where the
key molecules in T-cell signaling are localized (Manes et al.,
2003). HIV virions are released from infected cells by
budding from such lipid rafts (Nguyen and Hildreth, 2000).
Conceivably, Nef phosphorylation by PKA could occur at
this site at the time of virion assembly, and phosphorylated
Nef could be packaged into viral particles. The PKA–Nef
interaction could also occur at the time of viral entry, as HIV
virions preferentially attach to lipid rafts when approaching
new target cells. Interfering with the mechanisms by which
HIV jump-starts its replication in resting primary cells could
have an impact on the overall level of viral turnover in vivo.
Having identified the specific molecular interaction between
HIV Nef and the catalytic subunit of PKA, we have
discovered a potential novel therapeutic target for HIV
infection.Materials and methods
Mass spectrometry of phosphorylated Nef
Wild-type HIVNL4-3 and SIVmac239 GST–Nef fusion
proteins were extracted directly from an SDS-polyacryla-mide gel and subjected to trypsin digestion. The products of
digestion were analyzed by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) technique.
Vector constructions
After sequence verification, all wild-type and mutant nef
genes were cloned into the pGEX-6p-1 vector (Amersham
Pharmacia Biotech, Piscataway, NJ) for GST Nef–fusion
protein expression. For mammalian expression, we used the
pcDNA6/myc-His/B vector (Invitrogen Life Technologies,
Carlsbad, CA).
Generation of point mutations in the nef coding region in
the context of full-length HIVNL4-3
Following the manufacturer’s instructions with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA), we generated two full-length HIVNL4-3
mutants: single-mutant HIV S9A, with Ser9 changed to
Ala, and double-mutant HIV S6,9A, with both Ser6 and Ser9
changed to Ala.
GST–Nef fusion proteins
GST–Nef fusion proteins and GST protein alone were
expressed in Escherichia coli BL-21 cells and purified using
GST TrapTM FF columns (Amersham Pharmacia Biotech).
The GST–Nef fusion protein sequences were further
confirmed by mass spectral analysis in the Molecular
Biology Core Facility of the Dana-Farber Cancer Institute.
In vitro PKA assay
The assay contained 20 ACi [32g-P] ATP (Perkin-Elmer,
Boston, MA), 20 units PKA catalytic subunit (Promega,
Madison, WI), and either HIV GST–Nef fusion proteins
(100 Ag), SIV GST–Nef fusion proteins (50 Ag), or GST
protein alone (100 Ag), respectively, and was performed
according to the manufacturer’s instructions. To quantitate
32P incorporation into GST–Nef fusion proteins, 50 Al of the
reaction was spotted onto Whatman P-81 filters (Whatman,
Maidstone, UK); 32P was counted using a 1410 Liquid
Scintillation Counter (Perkin-Elmer). To qualitatively assess
32P incorporation into GST–Nef fusion proteins, the
samples were analyzed by 10% SDS-PAGE and autoradio-
graphed. Then, the bands were excised, and we used mass
spectral analysis to locate the phosphorylation sites.
For stoichiometric analysis, the ATP and PKA
catalytic subunit concentrations were held constant at
2.5 ACi [32g-P]ATP (Perkin-Elmer), and 20 units of PKA
catalytic subunit, respectively, and the GST–Nef fusion
proteins were varied from 0.1 to 100 AM in a final
reaction volume of 50 Al. The reaction was performed for
30 min according to the manufacturer’s instructions.
Aliquots (25 Al) were spotted onto Whatman P-81 filters;
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in triplicate. Kinetic data were analyzed by nonlinear
regression to fit the data to the Michaelis–Menten
equation: V = Vmax[X] / (Km + [X]) by using PRISM
(GraphRad Prism version 4.0, San Diego, CA), where V
is the velocity, Vmax is the maximal velocity, Km is the
Michaelis Constant, and X is the substrate concentration.
Co-immunoprecipitation of Nef with PKA
293T cells were transfected with the pcDNA6/myc-His/B
encoding wild-type HIVNL4-3 nef or an empty vector using
the ProFection Mammalian Transfection System-Calcium
Phosphate (Promega). At 36 h post-transfection, cells were
stimulated with forskolin (Sigma, St. Louis, MO) (30 Am for
30min). The cells were washed with cold phosphate-buffered
saline (PBS) twice and lysed with 2 ml cold lysis buffer (1%
Triton X-100, 50 mM Tris–HCl (pH 7.5), 1 mM EDTA,
1 mM EGTA, 0.27Msucrose, 10mMNa4P2O7, 50mMNaF,
1 mM Na3VO4, 1 AM Microcystin-LR, 0.1% 2-mercaptoe-
thanol, 10Al/ml protease inhibitor cocktail (Sigma), and1mM
PMSF). The lysates were subjected to immunoprecipitation
with anti-HIV Nef serum (AIDS Reagent and Reference
Reagent Program (ARRRP)) overnight at 4 8C. Then, 50 Al of
protein A/Sepharose (Amersham Pharmacia Biotech) was
added, and the incubation continued for 2 h more. Immuno-
precipitates were washed 10 times with 1 ml of cold wash
buffer (lysis buffer plus 0.5 M NaCl) and eluted from protein
A/Sepharose with 50 Al of elution buffer (1 M glycine and
0.25 M NaCl, pH 2.8). Eluates were analyzed by 10% SDS-
PAGE and transferred to a nitrocellulose membrane (Invi-
trogen), which was treated with blocking buffer (5% fat-free
milk containing 50 mM Tris–HCl (pH 7.5), 0.2 m NaCl and
0.2% (by volume) Tween 20), followed by overnight
incubation at 4 8C with blocking buffer containing either
monoclonal antibody (mAb) to HIVNef (ARRRP) or to PKA
(BD Biosciences, San Diego, CA). Bands were visualized
with goat anti-mouse IgG-conjugated horseradish peroxidase
(HRP) (BIO-RAD, Hercules, CA) and FAT DAB tablet
(Sigma).
Nef phosphorylation in 293T cells
293T cells were transfected as described above, and 24 h
post-transfection, the cells were washed with phosphate-free
complete DMEM medium (10% fetal bovine serum (FBS),
2 mM l-glutamine, 100 U/ml penicillin, and 100 Ag/ml
streptomycin) and incubated for another 12 h. The medium
was then replaced with fresh phosphate-free complete
DMEM containing 32P orthophosphate (1 mCi/ml) (Perkin-
Elmer). The cells were incubated for 4 h and stimulated with
30 Am forskolin, with or without 30 AM of the PKA inhibitor
H-89 (Sigma) for an additional 30 min. Nef was immuno-
precipitated as described above. After autoradiography, the
Nef bands were excised and dried, and 32P was counted
using a 1410 Liquid Scintillation Counter (Perkin-Elmer).The 32P-labeled band corresponding to Nef was excised from
the SDS gel and analyzed by mass spectroscopy.
Generation of virus stocks
293T cells were transfected with 50 Ag of proviral
plasmid HIVNL4-3 DNA containing wild-type or mutant nef
genes to generate HIVNL4-3 stocks or with 50 Ag of proviral
DNA encoding HIVDnef (HIVNL4-3nef/DS, gift of Drs. D.
Richman and C. Spina, University of California at San
Diego) plus 100 Ag of mammalian Nef-expression con-
structs or empty vector to generate stocks of nef-deleted-
HIV + Nef in trans as described above. At 72 h post-
transfection, supernatants were harvested, passed through a
22-Am pore-size filter (Millipore, Bedford, MA), and
standardized for p24 by antigen capture (Beckman Coulter,
Miami, FL).
Virus infection and replication assays
TZM-bl cells (ARRRP) were exposed to different viruses
generated by cotransfecting proviral DNA of HIVDnef
(HIVNL4-3nef/DS; Spina et al., 1994) and expression vectors
encoding either wild-type or mutant Nef proteins. The cells
were exposed to serial three-fold dilutions of cell-free
supernatants harvested from the cotransfected cells contain-
ing 40 Ag/ml DEAE-dextran (Sigma) in 96-well plates.
After 6 h exposure at 37 8C in an atmosphere of 5% CO2,
the viral fusion inhibitor T-20 (AnaSpec, San Jose, CA) was
added at a final concentration of 2 Ag/ml. After 48 h of
incubation, 100 Al of the Bright-Glo luciferase assay system
(Promega) was added to each well. The plates were read in a
Wallac Victor2 1420 multilabel counter (Perkin-Elmer) for
luciferase activity. All viral infection assays were performed
in triplicate.
PBMC were isolated from anonymous human donors by
Ficoll density gradient centrifugation. Resting PBMC were
exposed to virus for 3 h, washed three times with complete
medium (RPMI 1640 supplemented with 10%FBS, 100U/ml
penicillin, 100 Ag/ml streptomycin, and 2 mM glutamine),
then suspended in fresh complete medium and incubated at
378C in an atmosphere of 5% CO2. PBMC were stimulated
with phytohemagglutinin (PHA, 3 Ag/ml) (Sigma) and 5 U
of recombinant interleukin-2 (rIL-2) (Roche Applied
Science, Indianapolis, IN) per ml on day 4 post-infection
for 1 day. The cells were then washed with fresh medium
and resuspended in complete medium containing 5 U of
rIL-2/ml. Supernatants were collected and replaced with
fresh medium, and p24 Gag levels were measured. All virus
replication assays were performed in triplicate.
Statistical analysis
Data analysis was performed by the Student’s t test,
using Bonferroni’s correction for multiple comparisons
when indicated.
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